| metastatic/advanced mGC or mGEJC | |||
| mGC or mGEJC - L1 - HER2 neg/PDL1 positive | mGC or mGEJC - L1 - HER2 negative | mGC or mGEJC - L1 - PDL1 positive | |
| immune chekpoint inhibitors | |||
| anti-PD-(L)1 | |||
| nivolumab based treatment | |||
| nivolumab plus SoC | CheckMate 649 ... CheckMate 649 ... | CheckMate 649 | |
| pembrolizumab based treatment | |||
| pembrolizumab alone | KEYNOTE-062 ... KEYNOTE-062 ... | ||
| pembrolizumab plus SoC | KEYNOTE-062 ... KEYNOTE-062 ... | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
